BIBP COVID-19 vaccine

SARS-CoV-2 whole virus inactivated, produced in vero cells. Can also be referred to as more general Sinopharm COVID-19 vaccine. Do not confuse with Sinovac COVID-19 vaccine or sinopharm WIBP COVID-19 vaccine

Also Known As:

BBIBP CorV; BBIBP-CorV; BBIBP-CorV vaccine; BBIBP-CorV vaccine antigen; BBIBPCorV; BIBP vaccine; BIBP-CorV; Covilo; SARS-CoV-2 HB02 strain beta-propiolactone inactivated vaccine antigen; sinopharm BIBP COVID-19 vaccine; sinopharm's SARS-CoV-2 Beijing vaccine HB02 strain antigen

Networked: 129 relevant articles (13 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Inactivated Vaccines: 1604
      - BIBP COVID-19 vaccine: 129
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        BIBP COVID-19 vaccine: 129

Experts

1.	Etemadifar, Masoud: 3 articles (12/2022 - 01/2022)
2.	Nouri, Hosein: 3 articles (12/2022 - 01/2022)
3.	Salari, Mehri: 3 articles (12/2022 - 01/2022)
4.	Sedaghat, Nahad: 3 articles (12/2022 - 01/2022)
5.	Wang, Hui: 3 articles (01/2022 - 01/2020)
6.	Liu, Qiang: 2 articles (12/2022 - 01/2022)
7.	Abdalla, Jehad Saleh: 2 articles (11/2022 - 01/2022)
8.	Al Hosani, Farida Ismail: 2 articles (11/2022 - 01/2022)
9.	Al Kaabi, Nawal: 2 articles (11/2022 - 01/2022)
10.	Beiram, Rami: 2 articles (11/2022 - 01/2022)

Related Diseases

1.	COVID-19 04/24/2023 - "Our study found that the BBIBP-CorV vaccine was effective in protecting healthcare workers from COVID-19." 12/01/2022 - "BBIBP-CorV exerts efficient protection against SARS-CoV-2 infection. " 01/01/2022 - "Our findings support the use of a 4 μg dose and two-shot regimen BBIBP-CorV in phase 3 trials in the population younger than 18 years to further ascertain its safety and protection efficacy against COVID-19. " 10/01/2023 - "The inactivated BBIBP-CorV vaccine has shown safety, efficacy and immunogenicity against COVID-19 in in-vitro studies and clinical trials. " 10/08/2022 - "Our study suggests that inactivated BBIBP-CorV against SARS-CoV-2 could elicit modulations on gut microbial composition and functions, which might favor host immune response and protect from COVID-19."
2.	Infections 01/01/2020 - "Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. " 06/08/2023 - "A test negative case-control study design was used to assess safety and efficacy of BBIBP-CorV in individuals aged 60 and above against symptomatic infection, hospitalisations and mortality due to SARS-CoV-2 among vaccinated and unvaccinated individuals. " 11/01/2023 - "BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai." 11/01/2023 - "The existence of humoral memory responses established through BBIBP-CorV vaccination facilitates to induce rapid recall antibody responses when encountering SARS-CoV-2 variant infection." 11/01/2023 - "To investigate how BBIBP-CorV vaccination affecting antibody responses upon heterologous Omicron infection. "
3.	Neoplasms (Cancer) 01/01/2022 - "In the present prospective study, we aimed to evaluate severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody response with BBIBP-CorV vaccine in Iranian cancer patients. " 01/01/2022 - "SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study." 01/01/2022 - "Full vaccination of COVID-19 by BBIBP-CorV in immunocompromised patients such as cancer patients is safe and effective and could induce antibody response but in lower levels compared to healthy people. " 01/01/2022 - "Long-term safety and efficacy of BBIBP-CorV vaccine especially in individuals with chronic diseases, like cancer, is under investigation. " 01/01/2023 - "In total, 57 cancer patients who received BNT162b2-RNA or BBIBP-CorV vaccines were enrolled. "
4.	Chronic Disease (Chronic Diseases) 01/01/2022 - "Long-term safety and efficacy of BBIBP-CorV vaccine especially in individuals with chronic diseases, like cancer, is under investigation. "
5.	Multiple Sclerosis 10/15/2021 - "Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV." 03/01/2023 - "The objective of the present study was to estimate the effectiveness of the BBIBP-CorV vaccine (VE) in preventing SARS-CoV-2 infection, related hospitalization, and death among people living with multiple sclerosis (PLWMS). " 03/01/2023 - "Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study." 05/01/2022 - "The aim of this study was to evaluate the safety of Sinofarm vaccine (BBIBP-CorV) in patients with multiple sclerosis (pwMS). " 12/31/2022 - "To affirm the short-term safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among people with multiple sclerosis (pwMS), 517 vaccinated and 174 unvaccinated pwMS were interviewed. "

Related Drugs and Biologics

1.	BNT162 Vaccine
2.	Vaccines
3.	Messenger RNA (mRNA)
4.	sinovac COVID-19 vaccine
5.	2019-nCoV Vaccine mRNA-1273
6.	COVID-19 Vaccines
7.	Inactivated Vaccines
8.	mRNA Vaccines
9.	ChAdOx1 nCoV-19
10.	Ad26COVS1

Related Therapies and Procedures

1.	Renal Replacement Therapy (Therapies, Renal Replacement)
2.	Therapeutics
3.	Critical Care (Surgical Intensive Care)